검색어: antiparkinsoniki (슬로베니아어 - 영어)

antiparkinsoniki
anti-parkinson medicinal products

drugi antiparkinsoniki:
other antiparkinsonian medicinal products:

farmakoterapevtska skupina: antiparkinsoniki.
pharmaco-therapeutic group:

farmakoterapevtska skupina: antiparkinsoniki, zaviralci monoaminooksidaz tipa b, oznaka atc:
anti-parkinson-drugs, monoamine oxidase -b inhibitors, atc code:

farmakoterapevtska skupina: antiparkinsoniki, agonisti dopamina, oznaka atc: n04bc05.
pharmacotherapeutic group: anti-parkinson drugs, dopamine agonists, atc code: n04bc05

farmakoterapevtska skupina: antiparkinsoniki, dopaminergiki, oznaka atc: n04ba02 mehanizem delovanja
pharmacotherapeutic group: anti-parkinson drugs, dopaminergic agents, atc code: n04ba02 mechanism of action

vendar študij, ki bi obravnavale interakcije z antiparkinsoniki in tricikličnimi antidepresivi, niso opravili.
however, no studies involving the interaction with anti- parkinson agents and tricyclic antidepressants have been performed.

drugi antiparkinsoniki: do sedaj niso znane nobene interakcije, ki bi omejevale sočasno uporabo standardnih antiparkinsonikov in zdravila corbilta.
other antiparkinsonian medicinal products: to date there has been no indication of interactions that would preclude concurrent use of standard antiparkinsonian medicinal products with corbilta therapy.

sočasna uporaba olanzapina z antiparkinsoniki pri bolnikih s parkinsonovo boleznijo in demenco ni priporočena (glejte poglavje 4.4).
the concomitant use of olanzapine with anti-parkinsonian medicinal products in patients with parkinson's disease and dementia is not recommended (see section 4.4).

redko, potem ko vam nenadoma zelo zmanjšajo odmerek ali prekinejo zdravljenje z zdravilom tasmar ali drugimi antiparkinsoniki, lahko izkusite hude simptome togosti mišic, visoko vročino ali duševno zmedenost.
rarely, after abruptly reducing or stopping tasmar or other antiparkinsonian drugs, you may experience severe symptoms of muscle stiffening, fever or mental confusion.

drugi antiparkinsoniki: do sedaj niso znane nobene interakcije, ki bi omejevale sočasno uporabo standardnih antiparkinsonikov in zdravila levodopa/carbidopa/entacapone orion.
other antiparkinsonian medicinal products: to date there has been no indication of interactions that would preclude concurrent use of standard antiparkinsonian medicinal products with levodopa/carbidopa/entacapone orion therapy.

učinkovitost in varnost opikapona je bila pokazana v dveh s placebom in zdravilno učinkovino (le študija 1) nadzorovanih, dvojno slepih študijah 3. faze s 1.027 randomiziranimi odraslimi bolniki s parkinsonovo boleznijo, do 15 tednov zdravljenih z levodopo/ddci (samo ali v kombinaciji z drugimi antiparkinsoniki) in motoričnimi fluktuacijami na koncu odmernega obdobja.
the efficacy and safety of opicapone has been demonstrated in two phase 3 double-blind, placebo and active (study 1 only) controlled studies in 1,027 randomized adult patients with parkinson’s disease treated with levodopa/ddci (alone or in combination with other antiparkinsonian drugs) and end-of- dose motor fluctuations for up to 15 weeks.